Skip to main content
Top
Published in: Journal of Neural Transmission 5/2020

01-05-2020 | Mitochondriopathy | Neurology and Preclinical Neurological Studies - Review Article

The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson’s disease

Authors: Jeswinder Sian-Hulsmann, Peter Riederer

Published in: Journal of Neural Transmission | Issue 5/2020

Login to get access

Abstract

Misfolding of the protein α-synuclein contributes to the formation of the intracellular inclusion, Lewy bodies. Although these structures are not exclusive to Parkinson’s disease, nevertheless, their presence in the substantia nigra is mandatory for the pathological diagnosis of the disorder. Therefore, there must be a focus on the pathological mechanisms responsible for Lewy body generation. Recent studies have suggested that α-synuclein has the potential to operate as the enzyme ferrireductase. Perhaps in the early diseased state, overexpression or mutation of alpha-synuclein/ferrireductase invokes the dyshomeostasis of iron (III)/(II) only, while in advanced stages, accumulation of iron in particular areas of the brain follows. Furthermore, the loss of an important iron chelator, neuromelanin (due to dopaminergic neuronal death), may then result in the release and increase in unbound free iron. Iron could generate reactive oxygen species, which could instigate a torrent of cellular deleterious processes. In addition, loss of energy supply may contribute to the alteration in activity of enzymes involved in the mitochondrial respiratory chain and would, therefore, confer a vulnerability to the dopaminergic neurons in the substantia nigra. Therefore, the ferrireductase alpha-synuclein may hold the key for major pathology of Parkinson’s disease. In conclusion, we hypothesize that environmentally or genetically overexpressed and/or mutated α-synuclein/ferrireductase causes iron dyshomeostasis without increase of free iron concentration in the early phases of PD, while increased iron concentration accompanied by iron dyshomeostasis is a marker for progressed PD stages. It is essential to elucidate these degenerative mechanisms, so as to provide effective therapeutic treatment to halt or delay the progression of the illness already in the early phase of PD. The development of iron chelators seems to be a reasonable approach.
Literature
go back to reference Ben-Shachar D, Eshel G, Riederer P, Youdim MBH (1992) Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson’s disease. Ann Neurol 32:S105–S110PubMed Ben-Shachar D, Eshel G, Riederer P, Youdim MBH (1992) Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson’s disease. Ann Neurol 32:S105–S110PubMed
go back to reference Brown DR (2013) α-Synuclein as a ferrireductase. Biochem Soc Trans 41(6):1513–1517PubMed Brown DR (2013) α-Synuclein as a ferrireductase. Biochem Soc Trans 41(6):1513–1517PubMed
go back to reference Deas E, Cremades N, Angelova PR, Marthe HR, Ludtmann HR, Zhi Y, Chen S, Horrocks MH, Banushi B, Little D, Devine MJ, Gissen P, Klenerman D, Dobson CM, Wood NW, Gandhi S, Abramov AY (2017) Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease. Prog Neurobiol 155:96–119 Deas E, Cremades N, Angelova PR, Marthe HR, Ludtmann HR, Zhi Y, Chen S, Horrocks MH, Banushi B, Little D, Devine MJ, Gissen P, Klenerman D, Dobson CM, Wood NW, Gandhi S, Abramov AY (2017) Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease. Prog Neurobiol 155:96–119
go back to reference Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R (2014) Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 21(2):195–210PubMedPubMedCentral Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R (2014) Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 21(2):195–210PubMedPubMedCentral
go back to reference Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, Gouel F, Rolland AS, Duce JA, Devedjian JC, FAIRPARK-II, and FAIRALS-II studygroups (2020) Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis. J Neural Transm (Vienna). 127(2):189–203. https://doi.org/10.1007/s00702-019-02138-1(Epub 2020 Jan 7. Review) PubMed Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, Gouel F, Rolland AS, Duce JA, Devedjian JC, FAIRPARK-II, and FAIRALS-II studygroups (2020) Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis. J Neural Transm (Vienna). 127(2):189–203. https://​doi.​org/​10.​1007/​s00702-019-02138-1(Epub 2020 Jan 7. Review) PubMed
go back to reference Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52(6):1830–1836PubMed Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52(6):1830–1836PubMed
go back to reference Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FY, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative disorders affecting the basal ganglia. Brain 114(4):1953–1975PubMed Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FY, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative disorders affecting the basal ganglia. Brain 114(4):1953–1975PubMed
go back to reference Double K, Zecca L, Costo P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, Gerlach M (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 75:2583–2589PubMed Double K, Zecca L, Costo P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, Gerlach M (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 75:2583–2589PubMed
go back to reference Double KL, Gerlach M, Schünemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, Ben-Shachar D (2003) Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66(3):489–494PubMed Double KL, Gerlach M, Schünemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, Ben-Shachar D (2003) Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66(3):489–494PubMed
go back to reference Flagmeier P, Meisl G, Vendruscolo M, Knowles TP, Dobson CM, Buell AK, Céline AG (2016) Mutations associated with familial Parkinson’s disease alter the initiation and amplification steps of α-synuclein aggregation. Proc Natl Acad Sci USA 113(37):10328–10333PubMedPubMedCentral Flagmeier P, Meisl G, Vendruscolo M, Knowles TP, Dobson CM, Buell AK, Céline AG (2016) Mutations associated with familial Parkinson’s disease alter the initiation and amplification steps of α-synuclein aggregation. Proc Natl Acad Sci USA 113(37):10328–10333PubMedPubMedCentral
go back to reference Götz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, Riederer P, Gerlach M (2000) Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm (Vienna) 107(1):41–48 Götz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, Riederer P, Gerlach M (2000) Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm (Vienna) 107(1):41–48
go back to reference Grünewald A, Rygiel KA, Hepplewhite PD, Morris CM, Picard M, Turnbull DM (2016) Mitochondrial DNA depletion in respiratory chain-deficient Parkinson disease neurons. Annals Neurol 79(3):366–378 Grünewald A, Rygiel KA, Hepplewhite PD, Morris CM, Picard M, Turnbull DM (2016) Mitochondrial DNA depletion in respiratory chain-deficient Parkinson disease neurons. Annals Neurol 79(3):366–378
go back to reference Hamed MY, Silver J (1983) Studies on the reactions of ferric iron with glutathione and some related thiols. Part II. Complex formation in the pH range three to seven. Inorg Chim Acta 80:115–122 Hamed MY, Silver J (1983) Studies on the reactions of ferric iron with glutathione and some related thiols. Part II. Complex formation in the pH range three to seven. Inorg Chim Acta 80:115–122
go back to reference Hamed MY, Silver J, Wilson MT (1983) Studies on the reactions of ferric iron with glutathione and some related thiols. Part III. A study of the iron catalyzed oxidation of glutathione by molecular oxygen. Inorg Chim Acta 80:237–244 Hamed MY, Silver J, Wilson MT (1983) Studies on the reactions of ferric iron with glutathione and some related thiols. Part III. A study of the iron catalyzed oxidation of glutathione by molecular oxygen. Inorg Chim Acta 80:237–244
go back to reference Hebron ML, Lonskaya I, Moussa CE (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. Hum Mol Genet 22(16):3315–3328PubMedPubMedCentral Hebron ML, Lonskaya I, Moussa CE (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. Hum Mol Genet 22(16):3315–3328PubMedPubMedCentral
go back to reference Joppe K, Roser A-E, Maass F, Lingor P (2019) The contribution of iron to protein aggregation disorders in the central nervous system. Front Neurosci 13:15PubMedPubMedCentral Joppe K, Roser A-E, Maass F, Lingor P (2019) The contribution of iron to protein aggregation disorders in the central nervous system. Front Neurosci 13:15PubMedPubMedCentral
go back to reference Khan TR, Langford CH (1976) Kinetic and spectsophotometric studies of binding of iron(II1) by glutathione. Can J Chem 54:3192 Khan TR, Langford CH (1976) Kinetic and spectsophotometric studies of binding of iron(II1) by glutathione. Can J Chem 54:3192
go back to reference Langley J, He N, Huddleston DE, Chen S, Yan F, Crosson B, Factor S, Hu X (2019) Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts. Mov Disord 34(3):416–419PubMed Langley J, He N, Huddleston DE, Chen S, Yan F, Crosson B, Factor S, Hu X (2019) Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts. Mov Disord 34(3):416–419PubMed
go back to reference Liu JL, Fan YG, Yang ZS, Wang ZY, Guo C (2018) Iron and Alzheimer's disease: from pathogenesis to therapeutic implications. Front Neurosci 12:632PubMedPubMedCentral Liu JL, Fan YG, Yang ZS, Wang ZY, Guo C (2018) Iron and Alzheimer's disease: from pathogenesis to therapeutic implications. Front Neurosci 12:632PubMedPubMedCentral
go back to reference Martin LJ (2006) Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 65(12):1103–1110PubMed Martin LJ (2006) Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 65(12):1103–1110PubMed
go back to reference Martin-Ruiz C, Williams-Gray CH, Yarnall AJ, Boucher JJ, Lawson RA, Wijeyekoon RS, Barker RA, Kolenda C, Parker C, Burn DJ, Von Zglinicki T, Saretzki G (2020) Senescence and inflammatory markers for predicting clinical progression in Parkinson’s disease: the ICICLE-PD study. J Parkinson's Dis 10(1):193 Martin-Ruiz C, Williams-Gray CH, Yarnall AJ, Boucher JJ, Lawson RA, Wijeyekoon RS, Barker RA, Kolenda C, Parker C, Burn DJ, Von Zglinicki T, Saretzki G (2020) Senescence and inflammatory markers for predicting clinical progression in Parkinson’s disease: the ICICLE-PD study. J Parkinson's Dis 10(1):193
go back to reference Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163(3):1450–1455PubMed Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163(3):1450–1455PubMed
go back to reference Mogi M, Harada M, Kiuchi K, Kojima K, Kondo T, Narabayashi H, Rausch D, Riederer P, Jellinger K, Nagatsu T (1988) Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain. J Neural Transm 72(1):77–82PubMed Mogi M, Harada M, Kiuchi K, Kojima K, Kondo T, Narabayashi H, Rausch D, Riederer P, Jellinger K, Nagatsu T (1988) Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain. J Neural Transm 72(1):77–82PubMed
go back to reference Moors TE, Hoozemans JJ, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin MC, van de Berg WD (2017) Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Mol Neurodegener 12(1):11PubMedPubMedCentral Moors TE, Hoozemans JJ, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin MC, van de Berg WD (2017) Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Mol Neurodegener 12(1):11PubMedPubMedCentral
go back to reference Müller T, Kohlhepp W (2018) Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson's disease. Med Hypotheses 110:46–49PubMed Müller T, Kohlhepp W (2018) Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson's disease. Med Hypotheses 110:46–49PubMed
go back to reference Müller T, Trommer I, Muhlack S, Mueller BK (2016) Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson’s disease. J Neural Transm 123:401–406PubMed Müller T, Trommer I, Muhlack S, Mueller BK (2016) Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson’s disease. J Neural Transm 123:401–406PubMed
go back to reference Rausch WD, Hirata Y, Nagatsu T, Riederer P, Jellinger K (1988) Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J Neurochem 50(1):202–208PubMed Rausch WD, Hirata Y, Nagatsu T, Riederer P, Jellinger K (1988) Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J Neurochem 50(1):202–208PubMed
go back to reference Reichmann H, Riederer P (1989) Biochemische Analyse der Atmungskettenkomplexe verschiedener Hirnregionen von Patienten mit Morbus Parkinson. In: Symposium des BMFT Morbus Parkinson und andere Basalganglienerkrankun-gen, S. 44 (abstr.) Reichmann H, Riederer P (1989) Biochemische Analyse der Atmungskettenkomplexe verschiedener Hirnregionen von Patienten mit Morbus Parkinson. In: Symposium des BMFT Morbus Parkinson und andere Basalganglienerkrankun-gen, S. 44 (abstr.)
go back to reference Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52(2):515–520PubMed Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52(2):515–520PubMed
go back to reference Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Krüger R, Müller T, Reichmann H, Rieß O, Storch A, Strobel S, van Eimeren T, Völker HU, Winkler J, Winklhofer KF, Wüllner U, Zunke F, Monoranu CM (2019) α-Synuclein in Parkinson's disease: causal or bystander? J Neural Transm (Vienna) 126(7):815–840 Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Krüger R, Müller T, Reichmann H, Rieß O, Storch A, Strobel S, van Eimeren T, Völker HU, Winkler J, Winklhofer KF, Wüllner U, Zunke F, Monoranu CM (2019) α-Synuclein in Parkinson's disease: causal or bystander? J Neural Transm (Vienna) 126(7):815–840
go back to reference Sian J, Dexter DT, Jenner P, Marsden CD (1991) Decrease in nigral reduced glutathione in Parkinson’s disease. Br J Pharmacol 104:281P Sian J, Dexter DT, Jenner P, Marsden CD (1991) Decrease in nigral reduced glutathione in Parkinson’s disease. Br J Pharmacol 104:281P
go back to reference Sian J, Dexter D, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marden CD (1994) Alterations in glutathione in Parkinson’s disease and other neurodegenerative disorders affecting the basal ganglia. Ann Neurol 36(3):348–355PubMed Sian J, Dexter D, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marden CD (1994) Alterations in glutathione in Parkinson’s disease and other neurodegenerative disorders affecting the basal ganglia. Ann Neurol 36(3):348–355PubMed
go back to reference Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 118(6):939–957PubMed Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 118(6):939–957PubMed
go back to reference Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Trans 74:199–205 Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Trans 74:199–205
go back to reference Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142(2):128–130PubMed Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142(2):128–130PubMed
go back to reference Stockwell BR, Angeli JPF, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171(2):273–285. https://doi.org/10.1016/j.cell.2017.09.021 PubMedPubMedCentral Stockwell BR, Angeli JPF, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171(2):273–285. https://​doi.​org/​10.​1016/​j.​cell.​2017.​09.​021 PubMedPubMedCentral
go back to reference Talan J (2019) 3 Different clinical subtypes of Parkinson's disease. J Parkinsons Dis 5(4):699–713 Talan J (2019) 3 Different clinical subtypes of Parkinson's disease. J Parkinsons Dis 5(4):699–713
go back to reference Ward RJ, Crichton RR. (2019) Ironing out the Brain. Met Ions Life Sci. Jan 14;1 Ward RJ, Crichton RR. (2019) Ironing out the Brain. Met Ions Life Sci. Jan 14;1
go back to reference Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5(11):863–873PubMed Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5(11):863–873PubMed
go back to reference Zucca FA, Segura-Aguilar J, Ferrari E, Muñoz P, Paris I, Sulzer D, Sarna T, Casella L, Zecca L (2017) Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease. Prog Neurobiol 155:96–119PubMed Zucca FA, Segura-Aguilar J, Ferrari E, Muñoz P, Paris I, Sulzer D, Sarna T, Casella L, Zecca L (2017) Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease. Prog Neurobiol 155:96–119PubMed
go back to reference Zucca FA, Vanna R, Cupaioli FA, Bellei C, De Palma A, Di Silvestre D, Mauri P, Grassi S, Prinetti A, Casella L, Sulzer D, Zecca L (2018) Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson's disease. NPJ Parkinsons Dis 4:17PubMedPubMedCentral Zucca FA, Vanna R, Cupaioli FA, Bellei C, De Palma A, Di Silvestre D, Mauri P, Grassi S, Prinetti A, Casella L, Sulzer D, Zecca L (2018) Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson's disease. NPJ Parkinsons Dis 4:17PubMedPubMedCentral
Metadata
Title
The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson’s disease
Authors
Jeswinder Sian-Hulsmann
Peter Riederer
Publication date
01-05-2020
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 5/2020
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-020-02192-0

Other articles of this Issue 5/2020

Journal of Neural Transmission 5/2020 Go to the issue

Neurology and Preclinical Neurological Studies - Review Article

Selegiline: a molecule with innovative potential

Neurology and Preclinical Neurological Studies - Review Article

Treatment of tics associated with Tourette syndrome

Neurology and Preclinical Neurological Studies - Review Article

Parkinson’s disease treatment: past, present, and future

Neurology and Preclinical Neurological Studies - Review Article

Neuroprotection in Parkinson’s disease: facts and hopes